Mutant MT-SP1 proteases with altered substrate specificity or activity
US7939304B2 · kind B2 · utility
11Cited by
38References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2005 |
| Grant date | May 10, 2011 |
| Priority date | — |
| Expiry date | May 29, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.